GILEAD

Lykos Therapeutics Strengthens Commercial Organization with Key Hires as it Prepares for Potential Commercial Launch

Retrieved on: 
Venerdì, Maggio 3, 2024
Social stigma, FDA, University, Capsule, Social work, CCO, Simmons University, Safety, Food, Marketing, Coy, PTSD, MAPS, Market access, Policy, MDMA, Senior, Psychology, Bristol Myers Squibb, Cell biology, Patient advocacy, Multimedia, PBC, Therapy, SAN, McGill University, Pharmaceutical industry

Coy Stout has also joined Lykos as Vice President (VP) of Market Access,  a critical function in the growing commercial organization.

Key Points: 
  • Coy Stout has also joined Lykos as Vice President (VP) of Market Access,  a critical function in the growing commercial organization.
  • "The appointment of Allison, our first chief commercial officer, marks a critical milestone as we build out our commercial organization and prepare for a potential product launch of MDMA-assisted therapy if approved by the FDA," said Amy Emerson, Chief Executive Officer of Lykos Therapeutics.
  • Ms. Rosenthal brings to Lykos more than 25 years of pharmaceutical experience introducing innovative therapies.
  • At Lykos Therapeutics, a public benefit corporation (PBC) founded by MAPS, our mission is to transform mental healthcare.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
Martedì, Aprile 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
Mercoledì, Aprile 10, 2024
Mantle cell lymphoma, MCL, FDA, Cancer, Inflammation, DLBCL, Paclitaxel, Gilead Sciences, Research, PCNSL, Partnership, B-cell lymphoma, Trial of the century, STAT6, IND, CNS, Lymphoma, Patient, Rheumatoid arthritis, NHL, Chronic lymphocytic leukemia, Central nervous system, AACR, Neoplasm, Clinical trial, Annual general meeting, Therapy, Sanofi, Lymphoid leukemia, Non-Hodgkin lymphoma, Calendar, SAN, BTK, Pharmaceutical industry

SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.

Key Points: 
  • SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.
  • Nurix and Sanofi extended their ongoing research program for STAT6 (signal transducer and activator of transcription 6).
  • Nurix retains its option to co-develop and co-promote future products in the United States under programs for which Nurix has exercised its option.
  • Nurix presented new clinical data for NX-5948 at the American Association for Cancer Research (AACR) 2024 Annual Meeting.

Gilead Sciences Announces First Quarter 2024 Financial Results

Retrieved on: 
Giovedì, Aprile 25, 2024
Oncology, Health, Infectious Diseases, Hospitals, Other Health, Pharmaceutical, Biotechnology, Liver disease, FTC, John Hodgman, Remdesivir, Science, Tax rate, Acute lymphoblastic leukemia, Research, ETR, European, Axicabtagene ciloleucel, Acquisition, IPR, EPS, Research and development, HCV, HIV, Therapy, COVID-19, Growth, B-cell lymphoma, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.
  • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter 2024, compared to $0.80 in the same period in 2023.
  • Non-GAAP diluted (loss) EPS was $(1.32) in the first quarter 2024, compared to $1.37 in the same period in 2023.
  • During the first quarter 2024, Gilead paid dividends of $990 million and repurchased $400 million of common stock.

Lazard Reports First-Quarter 2024 Results

Retrieved on: 
Giovedì, Aprile 25, 2024
Professional Services, Finance, Debt-to-GDP ratio, Sale, Avison Young, Service provider, Schaeffler Group, Enviva, Vitesco Technologies, Weather, CSR Limited, Lazard, AbbVie, Thomson Reuters, Francisco Partners, SVB, The Weather Company, Conference, Euronext Paris, Rubicon, Mars, Endo International, Tax, Silicon, Lumen Technologies, AUM, Acquisition, Mars, Incorporated, Massimo Zanetti Beverage Group, AFE, Share repurchase, Bank statement, Name, Asset management, GAAP, Sixth Street Partners, Note, Telescopic sight

On April 24, 2024, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.

Key Points: 
  • On April 24, 2024, Lazard declared a quarterly dividend of $0.50 per share on its outstanding common stock.
  • Beginning in the first quarter of 2024, Lazard has updated the names of certain non-U.S. GAAP ("non-GAAP") measures and metrics.
  • We believe that presenting our results on an adjusted basis, in addition to the U.S. GAAP results, is a meaningful and useful way to compare our operating results across periods.
  • ET on April 25, 2024, to discuss the company’s financial results for the first quarter of 2024.

Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

Retrieved on: 
Martedì, Aprile 23, 2024
Research, Engineering, Manufacturing, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, APTX, AbbVie, MD, CNS, Baxter International, Boston Consulting Group, Patient, Management

Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.

Key Points: 
  • Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.
  • Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience.
  • He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company.
  • “We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company,” said Tentarix Chairman Donald Santel.

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

Retrieved on: 
Giovedì, Aprile 18, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, AIDS, Health, Science, Oncology, Biochemistry, Development, Bayer, HCV, Rutgers University, Biophysics, Communication, Baylor College of Medicine, Beneficial ownership, Infection, HIV, Name, Therapy, Harvard University, Publication, Research and development, Supervisory board, Drug development, Natural science, Doctor of Philosophy, University, Agriculture, Cancer, Bangladesh Technical Education Board, Gilead Sciences, Syntex, Patient, Pleasure, MBA, Annual general meeting, HBV, Kronos

Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).

Key Points: 
  • Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).
  • The nomination of the two new independent directors demonstrates Vir’s commitment to ongoing Board refreshment.
  • Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, said: “We are incredibly excited about the prospect of adding such highly talented directors in Norbert and Ramy to the Board.
  • Previously, he served on the board of directors of Nimbus Therapeutics, a biotechnology company he helped found in 2009.

Aqtual Announces Appointment of Medical, Translational Research and Data Integrity Executives

Retrieved on: 
Martedì, Aprile 16, 2024
Doctor of Philosophy, Conditional sentence, Cancer, Gilead Sciences, Public health, Blood, Simon Fraser University, Virology, Research, McMaster University, University of California, Davis, Data integrity, Medicine, Molecular biology, Catalog, Disease, Imperial College London, Joint, DNA, Therapy, Public, Patient, GRAIL, MPH, Rheumatoid arthritis, Physician, Translational research, Data analysis, UC, Pharmaceutical industry

HAYWARD, Calif., April 16, 2024 /PRNewswire/ -- Aqtual, Inc., a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, today announced it has expanded its team to support the development of its molecular diagnostic test for rheumatoid arthritis (RA) therapy selection and its partnering efforts with companies across the pharma and biotech landscape. Signe Fransen has joined as Vice President of Scientific and Medical Affairs, Maggie Louie, Ph.D., has been appointed by Aqtual as Vice President of Translational Research and Strategic Partnerships, and Jason Carlson, MPH, has been brought on as Vice President of Data Integrity and GxP Systems.

Key Points: 
  • Signe Fransen has joined as Vice President of Scientific and Medical Affairs, Maggie Louie, Ph.D., has been appointed by Aqtual as Vice President of Translational Research and Strategic Partnerships, and Jason Carlson, MPH, has been brought on as Vice President of Data Integrity and GxP Systems.
  • We're excited to welcome Signe, Maggie, and Jason to the team to continue this momentum," said Diana Abdueva, Ph.D., co-founder and CEO of Aqtual.
  • Before her appointment at Aqtual, Maggie served as the Vice President of Research at Earli, where she led research initiatives focused on developing a novel synthetic biomarker platform for cancer diagnostics and therapeutics.
  • Mr. Carlson has decades of experience leading cross-functional teams to sustain data integrity, quality, and compliance throughout the product life cycle.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Giovedì, Aprile 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Giovedì, Aprile 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.